Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | GBA1 | P04062 | 6/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25978169 | 0.99 | EPHX2 (0.48) | EPHX2DRD2CNR1TRPV1HRH4 | |
| SCHEMBL18751721 | 0.91 | EPHX2 (0.43) | EPHX2DRD2 | |
| SCHEMBL25978186 | 0.91 | DRD2 (0.43) | EPHX2DRD2CNR1TRPV1HRH4 | |
| SCHEMBL25974527 | 0.90 | DGAT1 (0.41) | EPHX2DRD2 | |
| SCHEMBL25974529 | 0.90 | DGAT1 (0.41) | EPHX2DRD2 | |
| SCHEMBL25974519 | 0.89 | DGAT1 (0.42) | EPHX2DRD2 | |
| SCHEMBL25978188 | 0.88 | DGAT1 (0.40) | EPHX2DRD2 | |
| SCHEMBL20661430 | 0.88 | EPHX2 (0.42) | EPHX2DRD2 | |
| SCHEMBL25974525 | 0.88 | FOLH1 (0.42) | DRD2 | |
| SCHEMBL24916753 | 0.87 | EPHX2 (0.53) | EPHX2DRD2HRH4HRH3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | EPHX2 2667/4885DRD2 3308/4885CNR1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.